Renovis files $150 million shelf registration

By E. Janene Geiss

Philadelphia, Oct. 10 - Renovis, Inc. filed a $150 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers debt securities, common stock, preferred stock and warrants. The securities may be structured as convertibles.

The proceeds will be used for general corporate purposes, including clinical trials, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies, products and technologies that complement the company's business.

Renovis is a South San Francisco, Calif., biopharmaceutical company focusing on neurological and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.